Heart Failure Causally Linked to Chronic Kidney Disease
By Elana Gotkine HealthDay Reporter
TUESDAY, Dec. 19, 2023 -- Heart failure is causally associated with chronic kidney disease (CKD), according to a study published online Dec. 11 in PLOS ONE.
Junyu Zhang, from Hunan University of Chinese Medicine in Changsha, China, and colleagues used data from European populations, including 930,014 controls and 47,309 cases of heart failure from the HERMES consortium and 736,396 controls and 51,256 cases of CKD, to examine the relationship between heart failure and CKD. Several Mendelian randomization (MR) variations were employed to assess the bidirectional causal relationship.
The researchers found that the individuals with a genetic predisposition for heart failure had an elevated risk for CKD in the MR analysis. A significant association was revealed between the genetic prediction of heart failure and risk for CKD, as seen by the Inverse Variance Weighted (IVM) method (odds ratio, 1.12; 95 percent confidence interval, 1.03 to 1.21) and the Weighted Median Estimator (WME: odds ratio, 1.14; 95 percent confidence interval, 1.03 to 1.26). Even after conducting an MR analysis while adjusting for the effects of diabetes and hypertension, this causal relationship remained robust (odds ratios [95 percent confidence intervals] of 1.13 [1.03 to 1.23], 1.12 [0.85 to 1.48], and 1.15 [1.04 to 1.27] for IVM, MR-Egger, and WME, respectively). In reverse analyses, there was no significant causal link observed between CKD and heart failure.
"Unraveling the causal relationship between heart failure and CKD can offer new avenues for personalized medicine," the authors write. "Subsequent research should investigate the possibility of treatment modalities tailored to particular patient subgroups to reduce the risk and progression of both diseases."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
ASN: Empagliflozin Offers Lasting Cardiorenal Benefit in CKD Patients
MONDAY, Oct. 28, 2024 -- Empagliflozin continues to offer cardiorenal benefits for up to 12 months after discontinuation among patients with chronic kidney disease at risk for...
Comorbid Diabetes Increases Risk for Lower Extremity Amputation With Kidney Disease
FRIDAY, Oct. 18, 2024 -- Patients with comorbid diabetes have an elevated risk for lower extremity amputation (LEA) at all stages of chronic kidney disease (CKD) compared with...
Varying Dialysate Calcium Dosage Not Tied to Differences in All-Cause, Cardiovascular Mortality
FRIDAY, Oct. 18, 2024 -- There are no significant differences in all-cause or cardiovascular mortality with the prescription of dialysate calcium 1.50 versus 1.25 mmol/L for...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.